NCT04201782 - Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2011

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions

HIV-1-infection

Interventions

DRUG

There are no disallowed treatments

Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Trial Locations (4)

32803

Orlando Immunology Center, Orlando

78705

Central Texas Clinical Research, Austin

94115

Quest Clinical Research, San Francisco

06850

Circle CARE Center, LLC, Norwalk